Antiphospholipid syndrome (APS) is defined according to the Sydney 2006 criteria by the presence and persistence of at least 12 weeks of criteria aPL, including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), or anti-β2 glycoprotein I antibodies (aβ2GPI) in patients with a history or ongoing thrombotic events (arterial/venous) or pregnancy pathology [9]. The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.